FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mace Rothenberg

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Jeffrey R Infante; Suzanne F Jones; Vicki L Keedy; Hiroshi Kodaira; Wooin Lee; Mace L Rothenberg; Huali Wu; William C Zamboni; Johanna C Bendell; Emily Chan; Satoshi Ikeda; Howard A Burris
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Kenichi Sugihara; Thierry André; Silvano Brienza; Katsushige Gomi; Aimery Gramont; Po-Huang Lee; Nobuyuki Mizunuma; Atsushi Ohtsu; Mace L Rothenberg; Yasuhiro Shimada; Richard M Goldberg
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Andrea Wang-Gillam; Giliane Buzenet; Wendy Cooper; Jakob Dupont; Mace L Rothenberg; Jeffrey A Sosman; David R Spriggs; Lars Sternas; William P Tew; Albert Craig Lockhart
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mace Rothenberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jeffrey R Infante; Suzanne F Jones; Vicki L Keedy; Hiroshi Kodaira; Wooin Lee; Mace L Rothenberg; Huali Wu; William C Zamboni; Johanna C Bendell; Emily Chan; Satoshi Ikeda; Howard A Burris
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(5):699-705.
2012: Kenichi Sugihara; Thierry André; Silvano Brienza; Katsushige Gomi; Aimery Gramont; Po-Huang Lee; Nobuyuki Mizunuma; Atsushi Ohtsu; Mace L Rothenberg; Yasuhiro Shimada; Richard M Goldberg
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Cancer medicine 2012;1(2):198-206.
2012: Andrea Wang-Gillam; Giliane Buzenet; Wendy Cooper; Jakob Dupont; Mace L Rothenberg; Jeffrey A Sosman; David R Spriggs; Lars Sternas; William P Tew; Albert Craig Lockhart
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
Investigational new drugs 2012;30(5):1958-61.
2012: Kenichi Sugihara; Thierry André; Silvano Brienza; Aimery de Gramont; Richard M Goldberg; Po-Huang Lee; Nobuyuki Mizunuma; Atsushi Ohtsu; Mace L Rothenberg; Yasuhiro Shimada; Katsushige Gomi
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Clinical colorectal cancer 2012;11(2):127-37.
2011: Emily Chan; Christine H Chung; Robert J Coffey; Bonnie Lafleur; Albert Craig Lockhart; Nipun Merchant; Mace L Rothenberg; Bakula Trivedi; Jordan D Berlin
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.
American journal of clinical oncology 2011;34(6):581-6.
2011: Christine H Chung; Joseph M Aulino; Brian B Burkey; Kevin Palka; Joel Parker; Paula R Pohlmann; Igor Puzanov; Mace L Rothenberg; Barbara Murphy
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
Head & neck 2011;33(12):1804-8.
2011: Igor Puzanov; Wooin Lee; Alice P Chen; M Wade Calcutt; David L Hachey; Wendy L Vermeulen; Victoria J Spanswick; Chih-Yi Liao; John A Hartley; Jordan D Berlin; Mace L Rothenberg
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(11):3794-802.
2010: A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David Spriggs; William P Tew
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):207-14.
2009: Elizabeth Poplin; Yang Feng; Jordan Berlin; Mace L Rothenberg; Howard Hochster; Edith Mitchell; Steven Alberts; Peter O'Dwyer; Daniel Haller; Paul Catalano; David Cella; Al Bowen Benson
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3778-85.
2009: A Craig Lockhart; Emiliano Calvo; Anthony W Tolcher; Eric K Rowinsky; Gareth Shackleton; J Gilmour Morrison; Rezvan Rafi; Wendy VerMeulen; Mace L Rothenberg
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors.
American journal of clinical oncology 2009;32(1):9-14.
2009: Jane D Robertson; Nick A Botwood; Mace L Rothenberg; Hans-Joachim Schmoll
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Clinical colorectal cancer 2009;8(1):59-60.
2008: Alejandro D Ricart; Jordan D Berlin; Kyriakos P Papadopoulos; Samira Syed; Daniel W Drolet; Charlotte Quaratino-Baker; Julie Horan; Jon Chick; Wendy Vermeulen; Anthony W Tolcher; Eric K Rowinsky; Mace L Rothenberg
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7947-55.
2008: H Charles Manning; Nipun B Merchant; A Coe Foutch; John M Virostko; Shelby K Wyatt; Chirayu Shah; Eliot T McKinley; Jingping Xie; Nathan J Mutic; M Kay Washington; Bonnie J Lafleur; Mohammed Noor Tantawy; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Mace L Rothenberg; Darryl J Bornhop; John C Gore; Robert J Coffey
Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7413-22.
2008: Laura W Goff; Mace L Rothenberg; A Craig Lockhart; Bruce J Roth; Wendy L VerMeulen; Emily Chan; Jordan D Berlin
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
American journal of clinical oncology 2008;31(5):413-6.
2008: Daniel G Haller; Mace L Rothenberg; Alfred O Wong; Piotr M Koralewski; Wilson H Miller; Gyorgy Bodoky; Nassir Habboubi; Carlos Garay; Luis O Olivatto
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4544-50.
2008: Mace L Rothenberg; J V Cox; C Butts; M Navarro; Y-J Bang; R Goel; S Gollins; L L Siu; S Laguerre; D Cunningham
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1720-6.
2008: Peter J O'Brien; Rajeev Ramanathan; Jonathan M Yingling; Jose Baselga; Mace L Rothenberg; Michael A Carducci; Thomas Daly; Dorothy Adcock; Michael Lahn
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.
Biologics : targets & therapy 2008;2(3):563-9.
2008: Daniel G Stover; A Craig Lockhart; Jordan D Berlin; Emily Chan; Alan B Sandler; Jeffrey A Sosman; Victoria Middlebrook; Steven Nicol; Mace L Rothenberg
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Investigational new drugs 2008;26(4):339-45.
2008: Lia Gore; Mace L Rothenberg; Cindy L O'Bryant; Mary Kay Schultz; Alan B Sandler; Denise Coffin; Candice McCoy; Astrid Schott; Catherine Scholz; S Gail Eckhardt
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4517-25.
2008: Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2118-23.
2008: Jose Baselga; Mace L Rothenberg; Josep Tabernero; Joan Seoane; Thomas Daly; Ann Cleverly; Brandi Berry; Susanne K Rhoades; Chad A Ray; Jeffrey Fill; Daphne L Farrington; Lisa Anne Wallace; Jonathan M Yingling; Michael Lahn; Carlos L Arteaga; Michael A Carducci
TGF-beta signalling-related markers in cancer patients with bone metastasis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(2):217-36.
2008: Nipun B Merchant; Igor Voskresensky; Christopher M Rogers; Bonnie J Lafleur; Peter J Dempsey; Ramona Graves-Deal; Frank Revetta; A Coe Foutch; Mace L Rothenberg; M Kay Washington; Robert J Coffey
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1182-91.
2008: M Wade Calcutt; Wooin Lee; Igor Puzanov; Mace L Rothenberg; David L Hachey
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
Journal of mass spectrometry : JMS 2008;43(1):42-52.
2007: Gautam Rao; Marta Crispens; Mace L Rothenberg
Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(20):2867-72.
2007: A Craig Lockhart; R Bukowski; Mace L Rothenberg; K K Wang; W Cooper; J Grover; Leonard J Appleman; P R Mayer; M Shapiro; Andrew X Zhu
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Cancer chemotherapy and pharmacology 2007;60(2):203-9.
2007: Jeffrey M Albert; Carolyn Cao; Kwang Woon Kim; Christopher Willey; Ling Geng; Dakai Xiao; Hong Wang; Alan B Sandler; David H Johnson; Alexander D Colevas; Jennifer Low; Mace L Rothenberg; Bo Lu
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):3033-42.
2007: Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
The oncologist 2007;12(1):38-50.
2006: Yair Gazitt; Paul Shaughnessy; Mace L Rothenberg
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Oncology reports 2006;16(4):877-84.
2006: Richard M Goldberg; Isabelle Tabah-Fisch; Harry Bleiberg; Aimery de Gramont; Christophe Tournigand; Thierry Andre; Mace L Rothenberg; Erin Green; Daniel J Sargent
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4085-91.
2006: Larry J Schaaf; Lisa A Hammond; Stuart J Tipping; Richard M Goldberg; Rakesh Goel; John Kuhn; Langdon L Miller; Linda D Compton; Laura A Cisar; Gary L Elfring; Gabriela Gruia; J Patrick McGovren; Nicoletta Pirotta; Donghua Yin; Amarnath Sharma; Barbara A Duncan; Mace L Rothenberg
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3782-91.
2006: Kenneth R Hande; Anne Hagey; Jordan Berlin; Yingna Cai; Kysa Meek; Hiro Kobayashi; A Craig Lockhart; Diane Medina; Jeffrey A Sosman; Gary B Gordon; Mace L Rothenberg
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2834-40.
2006: A Craig Lockhart; Gillian F Cropp; Jordan D Berlin; Edwin F Donnelly; Robert D Schumaker; Larry J Schaaf; Kenneth R Hande; Arthur C Fleischer; Alison L Hannah; Mace L Rothenberg
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
American journal of clinical oncology 2006;29(2):109-15.
2006: Maurie Markman; P Y Liu; Mace L Rothenberg; Bradley J Monk; Mark Brady; David S Alberts
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1454-8.
2005: Mace L Rothenberg; Bonnie J Lafleur; Donna E Levy; M Kay Washington; Sherry L Morgan-Meadows; Ramesh K Ramanathan; Jordan D Berlin; Al B Benson; Robert J Coffey
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9265-74.
2005: Hiroyuki Kobayashi; S Gail Eckhardt; Jennifer A Lockridge; Mace L Rothenberg; Alan B Sandler; Cindy L O'Bryant; Wendy Cooper; Scott N Holden; Roger D Aitchison; Nassim Usman; Maurice Wolin; Michele L Basche
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;56(4):329-36.
2005: A Craig Lockhart; Mace L Rothenberg; Jordan D Berlin
Treatment for pancreatic cancer: current therapy and continued progress.
Gastroenterology 2005;128(6):1642-54.
2005: allan chen; Shyh-Jen Shih; Liza N Garriques; Mace L Rothenberg; Michael Hsiao; Dennis P Curran
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Molecular cancer therapeutics 2005;4(2):317-24.
2005: Wooin Lee; A Craig Lockhart; Richard B Kim; Mace L Rothenberg
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
The oncologist 2005;10(2):104-11.
2004: Mace L Rothenberg; Ping-Yu Liu; Sharon P Wilczynski; William A Nahhas; Gaye L Winakur; Caroline S Jiang; Carol M Moinpour; Ben Lyons; Geoffrey R Weiss; James H Essell; Harriet O Smith; Maurie Markman; David S Alberts
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Gynecologic oncology 2004;95(3):506-12.
2004: allan chen; Shyh-Jen Shih; Michael Hsiao; Mace L Rothenberg; Michelle Prudhomme
Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I.
Molecular pharmacology 2004;66(3):553-60.
2004: Mace L Rothenberg
Current status of second-line therapy for metastatic colorectal cancer.
Clinical colorectal cancer 2004;4 Suppl 1():S16-21.
2004: David S Alberts; Caroline Jiang; Ping-Yu Liu; Sharon P Wilczynski; Maurie Markman; Mace L Rothenberg
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(2):224-8.
2004: A Craig Lockhart; Martin Howard; Kenneth R Hande; Bruce J Roth; Jordan D Berlin; Franzanne Vreeland; Angela Campbell; Erminia Fontana; francesco Fiorentini; Camilla Fowst; Victoria A Paty; Odessa Lankford; Mace L Rothenberg
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(2):468-75.
2003: Mace L Rothenberg; Jordan D Berlin
Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3716-7.
2003: Patricia M LoRusso; Roy S Herbst; Danny Rischin; Malcolm Ranson; Hilary Calvert; Eric Raymond; Dirk Kieback; Stan Kaye; Luca Gianni; Adrian Harris; Thomas Bjork; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; Andrea Feyereislova; Anne Heyes; Steven D Averbuch; Judith S Ochs; José Baselga
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2040-8.
2003: Mace L Rothenberg; Amit Oza; Robert H Bigelow; Jordan D Berlin; John L Marshall; Ramesh K Ramanathan; Lowell L Hart; Sunil Gupta; Carlos A Garay; Brent G Burger; Nathalie Le Bail; Daniel G Haller
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2059-69.
2003: Jordan D Berlin; Mace L Rothenberg
Chemotherapeutic advances in pancreatic cancer.
Current oncology reports 2003;5(3):219-26.
2003: Neal J Meropol; Robert A Somer; John Gutheil; Robert J Pelley; Manuel R Modiano; Eric K Rowinsky; Mace L Rothenberg; Spencer Redding; Cuneyt M Serdar; Bin Yao; Robert Heard; Lee S Rosen
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1452-8.
2003: Mace L Rothenberg; David P Carbone; David H Johnson
Improving the evaluation of new cancer treatments: challenges and opportunities.
Nature reviews. Cancer 2003;3(4):303-9.
2003: Mace L Rothenberg; Ping-Yu Liu; Patricia S Braly; Sharon P Wilczynski; Edward V Hannigan; Scott Wadler; Gavin Stuart; Caroline Jiang; Maurie Markman; David S Alberts
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1313-9.
2002: Mace L Rothenberg
Current status of capecitabine in the treatment of colorectal cancer.
Oncology (Williston Park, N.Y.) 2002;16(12 Suppl No 14):16-22.
2002: Mace L Rothenberg; Jacqueline K Benedetti; John S Macdonald; Thomas E Seay; M A Neubauer; C S George; M S Tanaka; Jeffrey K Giguere; B T Pruitt; James L Abbruzzese
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(10):1576-82.
2002: David S Alberts; Maurie Markman; Deborah K Armstrong; Mace L Rothenberg; Franco Muggia; Stephen B Howell
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):3944-6.
2002: Roy S Herbst; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; José Baselga; Federico Rojo; Waun Ki Hong; Helen Swaisland; Steven D Averbuch; Judith S Ochs; Patricia M LoRusso
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3815-25.
2001: Mace L Rothenberg; John Kuhn; L J Schaaf; Gladys I Rodriguez; S Gail Eckhardt; Miguel A Villalona-Calero; David A Rinaldi; Lisa A Hammond; S Hodges; A Sharma; Gary L Elfring; R G Petit; Paula K Locker; Langdon L Miller; Daniel Von Hoff
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1631-41.
2001: Charles D Blanke; D G Haller; A B Benson; Mace L Rothenberg; Jordan Berlin; Motomi Mori; Y C Hsieh; L L Miller
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1575-80.
2001: Mace L Rothenberg; N J Meropol; E A Poplin; E Van Cutsem; Scott Wadler
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3801-7.
2001: Mace L Rothenberg; Ping-Yu Liu; Sharon P Wilczynski; Edward V Hannigan; S A Weiner; Geoffrey R Weiss; V J Hunter; J A Chapman; A Tiersten; P C Kohler; David S Alberts
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Gynecologic oncology 2001;82(2):317-22.
2001: Mace L Rothenberg
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
The oncologist 2001;6(1):66-80.
2000: Mace L Rothenberg
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 11):9-14.
2000: A R Nelson; Barbara Fingleton; Mace L Rothenberg; L M Matrisian
Matrix metalloproteinases: biologic activity and clinical implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1135-49.
2000: allan chen; P B Scruggs; Ling Geng; Mace L Rothenberg; Dennis E Hallahan
p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells.
Annals of the New York Academy of Sciences 2000;922():298-300.
1999: Mace L Rothenberg; Charles D Blanke
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Seminars in oncology 1999;26(6):632-9.
1999: allan chen; Hak Choy; Mace L Rothenberg
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):39-46.
1999: AM Storniolo; N H Enas; C A Brown; M Voi; Mace L Rothenberg; Richard L Schilsky
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
Cancer 1999;85(6):1261-8.
1999: Mace L Rothenberg; J V Cox; Russell F DeVore; J D Hainsworth; R Pazdur; S E Rivkin; J S Macdonald; C E Geyer; J Sandbach; D L Wolf; J S Mohrland; Gary L Elfring; Langdon L Miller; Daniel Von Hoff
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Cancer 1999;85(4):786-95.
1999: Ronald L Drengler; John Kuhn; Larry J Schaaf; Gladys I Rodriguez; Miguel A Villalona-Calero; Lisa A Hammond; J A Stephenson; S Hodges; Maura Kraynak; B A Staton; Gary L Elfring; Paula K Locker; Langdon L Miller; Daniel Von Hoff; Mace L Rothenberg
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):685-96.
1999: Carolyn D Britten; L Hammond; Manuel Hidalgo; Mace L Rothenberg; A Sharma; Sunil Sharma; Lillian Siu; Miguel A Villalona-Calero; Geoffrey R Weiss
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1999;18():178-209.
1999: Mace L Rothenberg; A R Nelson; Kenneth R Hande
New drugs on the horizon: matrix metalloproteinase inhibitors.
Stem cells (Dayton, Ohio) 1999;17(4):237-40.
1998: Mace L Rothenberg
Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Seminars in oncology 1998;25(5 Suppl 11):39-46.
1998: Yair Gazitt; Mace L Rothenberg; S G Hilsenbeck; V Fey; Charles Thomas; W Montegomrey
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
International journal of oncology 1998;13(4):839-48.
1998: Mace L Rothenberg; John Kuhn; Larry J Schaaf; Ronald L Drengler; S Gail Eckhardt; Miguel A Villalona-Calero; L Hammond; Langdon L Miller; R G Petit; Eric K Rowinsky; Daniel Von Hoff
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: Mace L Rothenberg; A Sharma; Geoffrey R Weiss; Miguel A Villalona-Calero; John R Eckardt; Cheryl Aylesworth; Maura Kraynak; David A Rinaldi; Gladys I Rodriguez; Howard A Burris; S Gail Eckhardt; CD Stephens; K Forral; S J Nicol; Daniel Von Hoff
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: Mace L Rothenberg
[New cancer therapies: balancing risk and benefit].
Gan to kagaku ryoho. Cancer & chemotherapy 1998;25(6):797-9.
1998: S Gail Eckhardt; Sharyn D Baker; John R Eckardt; Thomas G Burke; D L Warner; John Kuhn; G Rodriguez; S Fields; A Thurman; Lon Smith; Mace L Rothenberg; L White; Paul Wissel; R Kunka; S DePee; D Littlefield; Howard A Burris; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1997: Mace L Rothenberg
Topoisomerase I inhibitors: review and update.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(9):837-55.
1997: Howard A Burris; M J Moore; J Andersen; M R Green; Mace L Rothenberg; M R Modiano; M C Cripps; Russell Portenoy; AM Storniolo; P Tarassoff; R Nelson; F A Dorr; CD Stephens; Daniel Von Hoff
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2403-13.
1997: J J Sharma; B Razvillas; CD Stephens; Susan G Hilsenbeck; A Sharma; Mace L Rothenberg
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
Investigational new drugs 1997;15(4):361-4.
1996: Mace L Rothenberg
The current status of irinotecan (CPT-11) in the United States.
Annals of the New York Academy of Sciences 1996;803():272-81.
1996: Mace L Rothenberg
New developments in chemotherapy for patients with advanced pancreatic cancer.
Oncology (Williston Park, N.Y.) 1996;10(9 Suppl):18-22.
1996: Mace L Rothenberg; J L Abbruzzese; M Moore; Russell Portenoy; J M Robertson; H J Wanebo
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.
Cancer 1996;78(3 Suppl):627-32.
1996: Mace L Rothenberg; M J Moore; M C Cripps; J S Andersen; Russell Portenoy; Howard A Burris; M R Green; P G Tarassoff; T D Brown; E S Casper; A M Storniolo; Daniel Von Hoff
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):347-53.
1996: Mace L Rothenberg; John R Eckardt; John Kuhn; Howard A Burris; James Nelson; Susan G Hilsenbeck; Gladys I Rodriguez; A M Thurman; L S Smith; S Gail Eckhardt; G R Weiss; Gary L Elfring; David A Rinaldi; Larry J Schaaf; Daniel Von Hoff
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: Mace L Rothenberg
CPT-11: an original spectrum of clinical activity.
Seminars in oncology 1996;23(1 Suppl 3):21-6.
1996: G R Weiss; H A Burris 3rd; John R Eckardt; S Gail Eckhardt; S M Fields; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg; A J Valley
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1996;16():132-67.
1994: John R Eckardt; E Campbell; Howard A Burris; G R Weiss; Gladys I Rodriguez; S M Fields; A M Thurman; N W Peacock; P Cobb; Mace L Rothenberg
A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.
American journal of clinical oncology 1994;17(6):498-501.
1994: Mace L Rothenberg
DNA ploidy and S-phase fraction as prognostic factors in cervical cancer.
Cancer treatment and research 1994;70():53-62.
1994: G R Weiss; Howard A Burris; John R Eckardt; S Fields; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1994;15():130-51.
1993: Mace L Rothenberg; John Kuhn; Howard A Burris; James Nelson; John R Eckardt; M Tristan-Morales; Susan G Hilsenbeck; G R Weiss; L S Smith; Gladys I Rodriguez
Phase I and pharmacokinetic trial of weekly CPT-11.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2194-204.
1993: G R Weiss; Howard A Burris; John R Eckardt; S Fields; R Johnson; T O'Rourke; Gladys I Rodriguez; Mace L Rothenberg; J Wall
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1993;14():118-28.
1992: Howard A Burris; Mace L Rothenberg; John Kuhn; Daniel Von Hoff
Clinical trials with the topoisomerase I inhibitors.
Seminars in oncology 1992;19(6):663-9.